Ipsen rises after Q3 beat, outlook hike

Ipsen SA

22/10/2025 08:27

** Shares in Ipsen IPN.PA rise around 5% after the French biopharma company reported better-than-expected Q3 results and upgraded its outlook

** Jefferies says Q3 sales at 915 million euros ($1.07 billion) came in 3% ahead, largely driven by a beat of its cancer drug Somatuline

** Ipsen now expects 2025 total sales growth of around 10.0% at CER vs its previous expectation of greater than 7.0% and core operating margin of around 35.0% of total sales vs greater than 32.0% previously

** J.P Morgan says the guidance raise implies 9% upgrades

to consensus 2025 core operating profit

** Ipsen also announced acquisition of Imcheck Therapeutics for 350 million euros, which Jefferies says will bolster its pipeline

($1 = 0.8575 euros)